Cargando…

MODL-22. DEVELOPING A REAL-TIME PERSONALIZED DRUG TESTING PLATFORM FOR PEDIATRIC CNS CANCERS

INTRODUCTION: The relatively small size of biopsied CNS tumors has presented a historical challenge for real-time drug screens. Moreover, in vivo assessment of drug response does not often benefit patients with aggressive gliomas given the relatively long time (>8 months) of tumor engraftment in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laternser, Sandra, Cosentino, Chiara Cianciolo, Przystal, Justyna M, Dettwiler, Susanne, Rushing, Elisabeth Jane, Gerber, Nicolas U, Stücklin, Ana Guerreiro, Prasad, Rachna, Grotzer, Michael, Krayenbühl, Niklaus, Müller, Sabine, Nazarian, Javad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Preclinical Models/Experimental Therapy/Drug Discovery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715439/ http://dx.doi.org/10.1093/neuonc/noaa222.595

Ejemplares similares

MODL-04. MODELING CNS HGNET-BCOR PATHOGENESIS USING NEURAL STEM CELLS
por: Nakata, Satoshi, et al.
Publicado: (2020)

MODL-14. SMALL MOLECULE TARGETING OF ONCOGENIC FGF2-FGFR SIGNALING IN BRAIN TUMORS
por: Kumar, Karthiga Santhana, et al.
Publicado: (2020)

MODL-26. CHILDREN’S BRAIN TUMOR NETWORK: ACCELERATING RESEARCH THROUGH COLLABORATION AND OPEN-SCIENCE
por: Lilly, Jena, et al.
Publicado: (2020)

MODL-02. TARGETING REPLICATION STRESS IN PEDIATRIC BRAIN TUMORS
por: Krausert, Sonja, et al.
Publicado: (2020)

MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
por: Sommerkamp, Alexander C, et al.
Publicado: (2020)

MODL-01. Targeting replication stress in pediatric brain tumors
por: Krausert, Sonja, et al.
Publicado: (2022)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

MODL-06. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA
por: Malhotra, Anshu, et al.
Publicado: (2020)

MODL-30. DISSECTING THE ROLE OF MULTI-CILIOGENESIS NETWORK IN CHOROID PLEXUS TUMOR
por: Zhao, Haotian, et al.
Publicado: (2020)

MODL-07. DNA methylation-based biobank of murine models for pediatric tumors
por: Zheng, Tuyu, et al.
Publicado: (2022)

MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE
por: Dismuke, Taylor, et al.
Publicado: (2020)

MODL-08. OPTIMIZATION OF A NOVEL LOCAL DELIVERY SYSTEM FOR THE TREATMENTS OF SUPRATENTORIAL EPENDYMOMA
por: Ruff, Lisa, et al.
Publicado: (2020)

MODL-13. GENETICALLY ENGINEERED PIG MODEL OF RHABDOID TUMOR PREDISPOSITION SYNDROME-1
por: Na, Brian, et al.
Publicado: (2020)

MODL-15. THE COMBINATION TREATMENT OF PARP INHIBITOR AND TMZ, OR DAG WILL BE PROMISING TREATMENT IN SF8628
por: Ohba, Shigeo, et al.
Publicado: (2020)

MODL-21. INTEGRATIVE APPROACHES IN FUNCTIONAL GENOMICS TO IDENTIFY GENETIC DEPENDENCIES IN PEDIATRIC BRAIN CANCER
por: Sun, Claire, et al.
Publicado: (2020)

MODL-28. IMMUNE PRIMING WITH INTERFERON-Γ COMBINED WITH EPIGENETIC MODULATION IN PEDIATRIC BRAIN TUMORS
por: Crotty, Erin, et al.
Publicado: (2020)

MODL-12. DEVELOPMENT OF A NOVEL IMMUNOCOMPETENT MOUSE MODEL FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Seblani, Maggie, et al.
Publicado: (2020)

MODL-29. EVALUATING TUMOR-IMMUNE INTERACTIONS IN MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Furnish, Robin, et al.
Publicado: (2020)

MODL-28. Patient-derived, three-dimensional organoid platform for pediatric brain tumor modeling
por: Baubet, Valerie, et al.
Publicado: (2022)

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
por: Kresbach, Catena, et al.
Publicado: (2022)

MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation
por: Kolodziejczak, Anna, et al.
Publicado: (2022)

MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors
por: Guadix, Sergio, et al.
Publicado: (2022)

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma
por: Zuckermann, Marc, et al.
Publicado: (2022)

MODL-23. DNA METHYLATION AND COPY NUMBER VARIATION PROFILE FOR CHARACTERIZATION OF PEDIATRIC BRAIN TUMOR PRIMARY CELL LINES
por: Pedace, Lucia, et al.
Publicado: (2020)

MODL-24. AN ORGANOTYPIC CHUNK CULTURE TECHNIQUE TO STUDY DISEASE MECHANISM AND DEVELOP TARGETED THERAPEUTICS FOR PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA
por: Vijmasi, Trinka, et al.
Publicado: (2020)

MODL-27. MEK INHIBITION WITH TRAMETINIB SLOWS PROGRESSION OF MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN ORTHOTOPIC XENOGRAFT MURINE MODEL
por: Mushrif, Sujata, et al.
Publicado: (2020)

MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION
por: Izquierdo, Elisa, et al.
Publicado: (2020)

MODL-16. ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
por: Liang, Muh-Lii, et al.
Publicado: (2020)

MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY
por: Galati, Melissa, et al.
Publicado: (2020)

MODL-31. Novel in vivo models of post-radiation recurrent pediatric high-grade glioma show increased susceptibility to MAPK inhibition
por: Knox, Aaron, et al.
Publicado: (2022)

MODL-02. A novelCre-conditionalcMYC-driven MB Group 3 transgenic mouse model shows traceable leptomeningeal dissemination.
por: Morcavallo, Alaide, et al.
Publicado: (2022)

MODL-09. FEASIBILITY OF ACUTE SLICE CULTURE-SINGLE CELL SEQUENCING DRUG SCREENING AS A TOOL TO SELECT THERAPY FOR CHILDREN WITH RELAPSED BRAIN TUMORS
por: Gampel, Bradley, et al.
Publicado: (2020)

MODL-31. RADIATION-DERIVED TREATMENT-RESISTANT PDX AND CELL CULTURE MODELS RECAPITULATE THE CHARACTERISTICS OF MATCHED PRIMARY/RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
por: Knox, Aaron J, et al.
Publicado: (2020)

MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG
por: Carvalho, Diana, et al.
Publicado: (2020)

MODL-27. An organotypic brain slice culture platform as a novel pre-clinical model for diffuse intrinsic pontine glioma and diffuse midline glioma
por: Mann, Breanna, et al.
Publicado: (2022)

MODL-30. Children’s Brain Tumor Network preclinical tumor models development and sharing platform: collaborative model empowering pediatric brain tumor discovery and global research.
por: Koptyra, Mateusz, et al.
Publicado: (2022)

MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS
por: Muldoon, Daniel, et al.
Publicado: (2020)

HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Cosentino, Chiara Cianciolo, et al.
Publicado: (2021)

HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: Mueller, Timothy, et al.
Publicado: (2021)

Correction to: Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes
por: Metzger, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f36a8c0ne6qqn3t3j7um602apg